(ANIX) Anixa Biosciences - Ratings and Ratios
CAR-T, Vaccine, Oncology, Breast, Ovarian
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 67.3% |
| Value at Risk 5%th | 89.9% |
| Relative Tail Risk | -18.74% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.74 |
| Alpha | 16.58 |
| CAGR/Max DD | -0.15 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.405 |
| Beta | 1.247 |
| Beta Downside | 1.152 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.32% |
| Mean DD | 41.56% |
| Median DD | 45.39% |
Description: ANIX Anixa Biosciences November 16, 2025
Anixa Biosciences (NASDAQ: ANIX) is a U.S. biotech focused on developing cell-based immunotherapies and therapeutic cancer vaccines for high-unmet-need oncology indications, notably a chimeric endocrine-receptor CAR-T platform for ovarian cancer and vaccine candidates targeting triple-negative breast cancer (TNBC) and ovarian cancer, with a broader discovery pipeline aimed at lung, colon, and prostate malignancies.
Key recent metrics (as of Q3 2024) include a cash runway of roughly $45 million, a 30 % YoY increase in R&D spend reflecting advancement of its CAR-T program into IND-enabling studies, and a partnership with a major academic center that could accelerate pre-clinical validation of its retired-protein vaccine targets. Sector-level drivers that affect Anixa’s outlook are the projected 12 % CAGR growth of the global CAR-T market (expected to exceed $13 billion by 2029) and a tightening biotech financing environment that has raised the cost of equity for early-stage firms, making cash efficiency a critical success factor.
If you want a data-rich, quantitative view of how Anixa’s valuation compares to peers, a quick look at ValueRay’s analyst dashboards can help you spot any pricing anomalies worth deeper investigation.
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.39 (>2.0%) and ΔFCFTA -2.21pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.39 (>3.0%) and CFO -6.84m > Net Income -11.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (32.5m) change vs 12m ago 1.32% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.68%; Δ -0.68pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.22 (EBITDA TTM -12.0m / Interest Expense TTM 5.05m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 31.91
| 1. Piotroski 0.0pt |
| 2. FCF Yield -7.70% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda 0.11 |
| 6. ROIC - WACC (= -46.01)% |
| 7. RoE -63.05% |
| 8. Rev. Trend -29.36% |
| 9. EPS Trend 59.43% |
What is the price of ANIX shares?
Over the past week, the price has changed by +5.13%, over one month by -37.16%, over three months by -20.19% and over the past year by +38.98%.
Is ANIX a buy, sell or hold?
- Strong Buy: 1
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ANIX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10 | 204.9% |
| Analysts Target Price | 10 | 204.9% |
| ValueRay Target Price | 3.4 | 2.1% |
ANIX Fundamental Data Overview January 08, 2026
P/S = 481.5351
P/B = 6.3077
Beta = 0.502
Revenue TTM = 0.0 USD
EBIT TTM = -6.17m USD
EBITDA TTM = -12.0m USD
Long Term Debt = 213.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 39.0k USD (from shortTermDebt, last quarter)
Debt = 213.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.28m USD (from netDebt column, last quarter)
Enterprise Value = 88.9m USD (104.7m + Debt 213.0k - CCE 16.0m)
Interest Coverage Ratio = -1.22 (Ebit TTM -6.17m / Interest Expense TTM 5.05m)
FCF Yield = -7.70% (FCF TTM -6.84m / Enterprise Value 88.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 9000 ) / Revenue TTM)
Tobins Q-Ratio = 5.03 (Enterprise Value 88.9m / Total Assets 17.7m)
Interest Expense / Debt = 23.94% (Interest Expense 51.0k / Debt 213.0k)
Taxrate = -1.13% (negative due to tax credits) (144.0k / -12.7m)
NOPAT = -6.24m (EBIT -6.17m * (1 - -1.13%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 8.45 (Total Current Assets 17.4m / Total Current Liabilities 2.07m)
Debt / Equity = 0.01 (Debt 213.0k / totalStockholderEquity, last quarter 16.6m)
Debt / EBITDA = 0.11 (negative EBITDA) (Net Debt -1.28m / EBITDA -12.0m)
Debt / FCF = 0.19 (negative FCF - burning cash) (Net Debt -1.28m / FCF TTM -6.84m)
Total Stockholder Equity = 17.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -62.97% (Net Income -11.1m / Total Assets 17.7m)
RoE = -63.05% (Net Income TTM -11.1m / Total Stockholder Equity 17.6m)
RoCE = -34.56% (EBIT -6.17m / Capital Employed (Equity 17.6m + L.T.Debt 213.0k))
RoIC = -35.37% (negative operating profit) (NOPAT -6.24m / Invested Capital 17.6m)
WACC = 10.64% (E(104.7m)/V(104.9m) * Re(10.61%) + D(213.0k)/V(104.9m) * Rd(23.94%) * (1-Tc(-0.01)))
Discount Rate = 10.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.22%
Fair Price DCF = unknown (Cash Flow -6.84m)
EPS Correlation: 59.43 | EPS CAGR: 107.5% | SUE: 4.0 | # QB: 2
Revenue Correlation: -29.36 | Revenue CAGR: -0.39% | SUE: 0.0 | # QB: 0
EPS next Year (2026-10-31): EPS=-0.38 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=-8.6% | Growth Revenue=+0.0%
Additional Sources for ANIX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle